Vitamin D Supplementation Reduces Renin-Angiotensin System Activity in Obesity

Mass General Brigham

Status: Completed

Conditions: Hypertension; Vitamin D Deficiency; Obesity

Treatments: Dietary Supplement: Vitamin D (cholecalciferol)

Study type: Interventional

Funder types: Other

Identifiers

NCT01068418

2009p002062

Details and patient eligibility

About

Hypothesis: Vitamin D supplementation lower renin-angiotensin system activity in obesity.

Specific Aim: To investigate whether Vitamin D supplementation in obesity improves the vascular sensitivity to angiotensin II.

Full description

Vitamin D deficiency and obesity are international epidemics that have both been associated with increased activity of the renin-angiotensin system (RAS). Because increased RAS activity is associated with cardiovascular disease, interventions to lower RAS will have favorable public health impacts.

This study aims to evaluate whether the supplementation of Vitamin D in obese subjects will lower local tissue RAS activity. RAS activity will be evaluated by cross-sectional measurement of RAS components and by quantifying the vascular response to an infusion of angiotensin II. Subjects will be studied while Vitamin D deficient, and will return for repeat study following Vitamin D supplementation, for comparison.

Enrollment: 26 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age < 65,
• Cr < 1.6,
• 25-hydroxyvitamin D < 25 ng/mL,
• BMI > 30 kg/m2,
• stage I hypertension.

Exclusion criteria

• diabetes,
• coronary heart disease,
• heart failure,
• renal failure,
• liver failure,
• hyperparathyroidism,
• granulomatous disease.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

26 participants in 1 patient group

Vitamin D3

Experimental group

Description:

15000IU of vitamin D3 daily: open-label, single-arm

Treatment:

Dietary Supplement: Vitamin D (cholecalciferol)